Cortigent, INC. (CRGT) — SEC Filings

Overview

Cortigent, INC. (CRGT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-1/A filed on Dec 2, 2025: Cortigent, Inc. (CRGT) is launching an initial public offering of 1,500,000 shares of common stock at an anticipated price of $10.00 per share, aiming to raise $15.0 million before expenses. The company, a pioneer in neurostimulation, is developing the Orion Visual Cortical Prosthesis System for art

Sentiment Summary

Across 9 filings, the sentiment breakdown is: 8 neutral, 1 mixed. The dominant filing sentiment for Cortigent, INC. is neutral.

Filing Type Overview

Cortigent, INC. (CRGT) has filed 9 S-1/A with the SEC between Feb 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (9)

• Cortigent Targets $10B Neurotech Market with IPO, Orion Vision System — S-1/A · Dec 2, 2025 Risk: high
  Cortigent, Inc. (CRGT) is launching an initial public offering of 1,500,000 shares of common stock at an anticipated price of $10.00 per share, aiming to raise
• Cortigent, Inc. Files S-1/A for IPO — S-1/A · Dec 11, 2024 Risk: medium
  Cortigent, Inc. filed an S-1/A amendment on December 11, 2024, for its initial public offering. The company, incorporated in Delaware, is based in Valencia, Cal
• Cortigent, Inc. Files S-1/A Amendment for IPO — S-1/A · Nov 20, 2024 Risk: medium
  Cortigent, Inc. filed an S-1/A amendment on November 20, 2024, for its initial public offering under registration number 333-270700. The company, incorporated i
• Cortigent, Inc. Files S-1/A Amendment for IPO — S-1/A · Sep 4, 2024 Risk: medium
  Cortigent, Inc. filed an S-1/A amendment on September 4, 2024, for its initial public offering. The company, incorporated in Delaware, is based in Valencia, Cal
• Cortigent, Inc. Amends IPO Registration — S-1/A · Aug 16, 2024 Risk: medium
  Cortigent, Inc. filed an S-1/A amendment on August 15, 2024, for its initial public offering under registration number 333-270700. The company, based in Valenci
• Cortigent, Inc. Files S-1/A Amendment for IPO — S-1/A · Jun 7, 2024 Risk: medium
  Cortigent, Inc. filed an S-1/A amendment on June 7, 2024, for its initial public offering under registration number 333-270700. The company, located in Valencia
• Cortigent, Inc. Amends IPO Registration Statement — S-1/A · May 23, 2024 Risk: medium
  Cortigent, Inc. filed an S-1/A amendment on May 23, 2024, for its initial public offering. The company, incorporated in Delaware, is based in Valencia, Californ
• Cortigent, Inc. Files Amendment No. 7 to S-1 Registration Statement — S-1/A · Mar 22, 2024 Risk: low
  Cortigent, Inc. (CRGT) filed a Amended IPO Registration (S-1/A) with the SEC on March 22, 2024. Cortigent, Inc. filed Amendment No. 7 to its Form S-1 Registrati
• Cortigent, Inc. Files Amendment No. 6 to S-1 Registration Statement — S-1/A · Feb 29, 2024 Risk: low
  Cortigent, Inc. (CRGT) filed a Amended IPO Registration (S-1/A) with the SEC on February 29, 2024. Cortigent, Inc. filed an S-1/A (Amendment No. 6) on February

Risk Profile

Risk Assessment: Of CRGT's 9 recent filings, 1 were flagged as high-risk, 6 as medium-risk, and 2 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Key Executives

• Jonathan Adams
• Aaron A. Grunfeld, Esq.
• Aaron A. Grunfeld

Industry Context

Cortigent operates in the advanced medical device sector, specifically focusing on neurostimulation for functional restoration. The artificial vision market is nascent, with limited approved solutions, while the stroke recovery market is a significant area of unmet need. Key industry trends include the increasing sophistication of implantable devices, advancements in neuroscience, and a growing demand for therapies addressing neurological deficits.

Top Tags

ipo (6) · sec-filing (6) · amendment (5) · IPO (3) · Cortigent (2) · CRGT (2) · S-1/A (2) · Neurostimulation (1) · Medical Devices (1) · Artificial Vision (1)

Key Numbers

• Anticipated initial public offering price per share: $10.00 — Basis for IPO valuation
• Shares offered in IPO: 1,500,000 — Number of common stock shares being sold to the public
• Vivani Medical's beneficial ownership post-IPO: 77% — Indicates Cortigent will be a 'controlled company'
• Estimated U.S. total addressable market for Orion: $4 billion — Potential market size for artificial vision system
• Estimated annual U.S. total addressable market for Stroke Recovery System: $6 billion — Potential market size for stroke recovery device
• Duration of Orion Early Feasibility Study: 6 years — Completed in March 2025, providing safety and efficacy data
• Number of patients who received Argus II implants: 350 — Historical commercialization of predecessor device
• Non-accountable expense allowance for underwriters: 1.0% — Additional cost to Cortigent in the IPO
• Additional shares available for over-allotment option: 225,000 — Underwriters' option to purchase more shares
• Total adverse events in Orion EFS: 17 — Reported across five patients through March 2025
• SEC File Number: 333-270700 — Identifies this specific registration
• SIC Code: 3845 — Industry classification for Electromedical & Electrotherapeutic Apparatus
• Fiscal Year End: 1231 — Indicates the company's financial year closes on December 31st.
• Phone Number: 818-833-5000 — Registrant's principal executive office phone number
• Registration Number: 333-270700 — Identifies the specific SEC registration for Cortigent, Inc.'s offering.

Related Companies

VANI

Frequently Asked Questions